GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Aarey Drugs & Pharmaceuticals Ltd (BOM:524412) » Definitions » ROE %

Aarey Drugs & Pharmaceuticals (BOM:524412) ROE % : 2.12% (As of Dec. 2024)


View and export this data going back to 1994. Start your Free Trial

What is Aarey Drugs & Pharmaceuticals ROE %?

ROE % is calculated as Net Income divided by its average Total Stockholders Equity over a certain period of time. Aarey Drugs & Pharmaceuticals's annualized net income for the quarter that ended in Dec. 2024 was ₹29 Mil. Aarey Drugs & Pharmaceuticals's average Total Stockholders Equity over the quarter that ended in Dec. 2024 was ₹1,356 Mil. Therefore, Aarey Drugs & Pharmaceuticals's annualized ROE % for the quarter that ended in Dec. 2024 was 2.12%.

The historical rank and industry rank for Aarey Drugs & Pharmaceuticals's ROE % or its related term are showing as below:

BOM:524412' s ROE % Range Over the Past 10 Years
Min: 3.11   Med: 6.33   Max: 12.92
Current: 4.42

During the past 13 years, Aarey Drugs & Pharmaceuticals's highest ROE % was 12.92%. The lowest was 3.11%. And the median was 6.33%.

BOM:524412's ROE % is ranked worse than
51.93% of 957 companies
in the Drug Manufacturers industry
Industry Median: 4.96 vs BOM:524412: 4.42

Aarey Drugs & Pharmaceuticals ROE % Historical Data

The historical data trend for Aarey Drugs & Pharmaceuticals's ROE % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Aarey Drugs & Pharmaceuticals ROE % Chart

Aarey Drugs & Pharmaceuticals Annual Data
Trend Mar15 Mar16 Mar17 Mar18 Mar19 Mar20 Mar21 Mar22 Mar23 Mar24
ROE %
Get a 7-Day Free Trial Premium Member Only Premium Member Only 6.48 6.81 6.17 3.26 3.74

Aarey Drugs & Pharmaceuticals Quarterly Data
Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24
ROE % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 3.44 6.48 3.73 4.71 2.12

Competitive Comparison of Aarey Drugs & Pharmaceuticals's ROE %

For the Drug Manufacturers - Specialty & Generic subindustry, Aarey Drugs & Pharmaceuticals's ROE %, along with its competitors' market caps and ROE % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Aarey Drugs & Pharmaceuticals's ROE % Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Aarey Drugs & Pharmaceuticals's ROE % distribution charts can be found below:

* The bar in red indicates where Aarey Drugs & Pharmaceuticals's ROE % falls into.


;
;

Aarey Drugs & Pharmaceuticals ROE % Calculation

Aarey Drugs & Pharmaceuticals's annualized ROE % for the fiscal year that ended in Mar. 2024 is calculated as

ROE %=Net Income (A: Mar. 2024 )/( (Total Stockholders Equity (A: Mar. 2023 )+Total Stockholders Equity (A: Mar. 2024 ))/ count )
=46.837/( (1174.084+1327.556)/ 2 )
=46.837/1250.82
=3.74 %

Aarey Drugs & Pharmaceuticals's annualized ROE % for the quarter that ended in Dec. 2024 is calculated as

ROE %=Net Income (Q: Dec. 2024 )/( (Total Stockholders Equity (Q: Sep. 2024 )+Total Stockholders Equity (Q: Dec. 2024 ))/ count )
=28.72/( (1355.912+0)/ 1 )
=28.72/1355.912
=2.12 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

In the calculation of annual ROE %, the net income of the last fiscal year and the average total shareholder equity over the fiscal year are used. In calculating the quarterly data, the net income data used here is four times the quarterly (Dec. 2024) net income data. ROE % is displayed in the 30-year financial page.


Aarey Drugs & Pharmaceuticals  (BOM:524412) ROE % Explanation

ROE % measures the rate of return on the ownership interest (shareholder's equity) of the common stock owners. It measures a firm's efficiency at generating profits from every unit of shareholders' equity (also known as net assets or assets minus liabilities). ROE % shows how well a company uses investment funds to generate earnings growth. ROE %s between 15% and 20% are considered desirable.

The factors that affect a company's ROE % can be illustrated with the three-step DuPont Analysis:

ROE %(Q: Dec. 2024 )
=Net Income/Total Stockholders Equity
=28.72/1355.912
=(Net Income / Revenue )*(Revenue / Total Assets)*(Total Assets / Total Stockholders Equity)
=(28.72 / 5351.544)*(5351.544 / 2745.281)*(2745.281 / 1355.912)
=Net Margin %*Asset Turnover*Equity Multiplier
=0.54 %*1.9494*2.0247
=ROA %*Equity Multiplier
=1.05 %*2.0247
=2.12 %

With this breakdown, it is clear that if a company grows its Net Profit Margin, its Asset Turnover, or its Leverage, it can grow its ROE %.

The factors that affect a company's ROE % can also be illustrated with the five-step DuPont Analysis:

ROE %(Q: Dec. 2024 )
=Net Income/Total Stockholders Equity
=28.72/1355.912
=(Net Income / Pre-Tax Income) * (Pre-Tax Income / Operating Income) * (Operating Income / Revenue) * (Revenue / Total Assets) * (Total Assets / Total Stockholders Equity)
= (28.72 / 55.98) * (55.98 / 64.82) * (64.82 / 5351.544) * (5351.544 / 2745.281) * (2745.281 / 1355.912)
= Tax Burden * Interest Burden * Operating Margin % * Asset Turnover * Equity Multiplier
= 0.513 * 0.8636 * 1.21 % * 1.9494 * 2.0247
=2.12 %

Note: The net income data used here is four times the quarterly (Dec. 2024) net income data. The Revenue data used here is four times the quarterly (Dec. 2024) revenue data. The same rule applies to Pre-Tax Income and Operating Income.
* In the five-step DuPont Analysis, Operating Income is only available for non-financial companies. Thus, for Insurance companies, we use EBIT as a substitution of Operating Income. For Banks, both Operating Income and EBIT is unavailable. Thus we combined Interest Burden and Operating Margin % into Pretax Margin %, and the DuPont Analysis is divided into four components instead.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Be Aware

Net Income is used.

Because a company can increase its ROE % by having more financial leverage, it is important to watch the equity multiplier when investing in high ROE % companies. Like ROA %, ROE % is calculated with only 12 months data. Fluctuations in company's earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective.

Asset light businesses require very few assets to generate very high earnings. Their ROE %s can be extremely high.


Aarey Drugs & Pharmaceuticals ROE % Related Terms

Thank you for viewing the detailed overview of Aarey Drugs & Pharmaceuticals's ROE % provided by GuruFocus.com. Please click on the following links to see related term pages.


Aarey Drugs & Pharmaceuticals Business Description

Traded in Other Exchanges
Address
340/348, Narshi Natha Street, 107, Sahakar Bhavan, Masjid Bunder, Mumbai, MH, IND, 400 009
Aarey Drugs & Pharmaceuticals Ltd is engaged in bulk drug manufacturing and offers products for industrial applications. The company manufactures active pharmaceutical ingredients, intermediates, and specialty chemicals. It is also involved in the trading of industrial solvents and chemicals. The products offered by the company include N-Methyl urea, Dimethyl urea, Mefenamic acid, Metformin, Doxaphylline, and BMD among others. The company principally carries out its business operations in India.

Aarey Drugs & Pharmaceuticals Headlines

No Headlines